RAMP myoglobin approval one step closer:
This article was originally published in Clinica
Response Biomedical has completed patient enrolment in the clinical trial of its myoglobin RAMP assay, for use in the diagnosis of heart attacks (see Clinica No 952, p 20). The Vancouver, British Columbia company was expected to file regulatory submissions with the US and Canadian regulatory agencies by the end of June, with approvals anticipated by the end of September.
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.